• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutics Corporation - Common Stock (NQ:UTHR)

    550.10 +0.94 (+0.17%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 840,641
    Open 553.49
    Bid (Size) 500.05 (40)
    Ask (Size) 560.00 (40)
    Prev. Close 549.16
    Today's Range 547.76 - 555.59
    52wk Range 409.07 - 609.35
    Shares Outstanding 44,891,523
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    3 Reasons to Avoid UTHR and 1 Stock to Buy Instead
    Since April 2026, United Therapeutics has been in a holding pattern, posting a small loss of 4.2% while floating around $541.72. The stock also fell short of... 
    Via StockStory
    News headline image
    Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet
    Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ... 
    Via StockStory
    Topics Intellectual Property

    Performance

    52-Week Range 9.7% below 52-week high
    550.10
    409.0752W Low 609.3552W High
    1 Week 1.5% below 1-week high
    524.791W Low 558.301W High

    United Therapeutics Corporation - Common Stock (UTHR) traded between $409.07 and $609.35 over the past 52 weeks and last traded at $550.10, 9.7% below its 52-week high. Over the past week it ranged between $524.79 and $558.30.

    Past 12 Months
    +1.6%
    +9.4%
    +2.7%
    -4.8%
    +10.7%
    +25.0%
    1W +$8.48
    1M +$47.40
    3M +$14.53
    6M -$27.53
    YTD +$53.38
    1Y +$110.04

    UTHR was +25.0% over the past year, -4.8% over six months, +10.7% year to date, +1.6% in the last week.

    12 Months vs Market
    UTHR
    +25.0%
    DIA
    +12.4%
    SPY
    +17.4%
    QQQ
    +23.9%
    IWM
    +13.7%

    Over the past 12 months UTHR returned +25.0% versus DIA (Dow) +12.4%, SPY (S&P 500) +17.4%, QQQ (Nasdaq 100) +23.9% and IWM (Russell 2000) +13.7%.

    Volume & Liquidity 1.23× 3-mo avg
    Today 840,641 3-mo avg 681.4K
    1W
    1.0M
    1M
    1.1M
    3M
    681.4K
    6M
    586.3K
    YTD
    555.9K
    1Y
    544.1K

    UTHR most recently traded 840,641 shares against a 3-month average daily volume of 681.4K.

    More News

    Read More
    News headline image
    1 Mid-Cap Stock to Research Further and 2 That Underwhelm
    Via StockStory
    News headline image
    United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
    From United Therapeutics
    Via Business Wire
    United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗
    Via Chartmill
    United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock ↗
    Via Chartmill
    United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗
    Via Chartmill
    United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗
    Via Chartmill
    News headline image
    Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today
    Via StockStory
    Topics Intellectual Property
    News headline image
    United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗
    Via MarketBeat
    News headline image
    Why United Therapeutics (UTHR) Shares Are Falling Today
    Via StockStory
    News headline image
    1 Cash-Heavy Stock to Target This Week and 2 We Question
    Via StockStory
    United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗
    Via Chartmill
    News headline image
    Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Profitable Stocks We’re Skeptical Of
    Via StockStory
    News headline image
    United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    3 Cash-Producing Stocks We Keep Off Our Radar
    Via StockStory
    News headline image
    United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
    From United Therapeutics Corporation
    Via Business Wire
    News headline image
    United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions
    Via StockStory
    Topics Earnings
    News headline image
    UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures
    Via StockStory

    Frequently Asked Questions

    Is United Therapeutics Corporation - Common Stock publicly traded?
    Yes, United Therapeutics Corporation - Common Stock is publicly traded.
    What exchange does United Therapeutics Corporation - Common Stock trade on?
    United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for United Therapeutics Corporation - Common Stock?
    The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
    What is the current price of United Therapeutics Corporation - Common Stock?
    The current price of United Therapeutics Corporation - Common Stock is 550.10
    When was United Therapeutics Corporation - Common Stock last traded?
    The last trade of United Therapeutics Corporation - Common Stock was at 10/12/26 04:00 PM ET
    What is the market capitalization of United Therapeutics Corporation - Common Stock?
    The market capitalization of United Therapeutics Corporation - Common Stock is 24.69B
    How many shares of United Therapeutics Corporation - Common Stock are outstanding?
    United Therapeutics Corporation - Common Stock has 25B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.